Brad Schenkel

2.4k total citations · 1 hit paper
62 papers, 1.9k citations indexed

About

Brad Schenkel is a scholar working on Immunology, Economics and Econometrics and Dermatology. According to data from OpenAlex, Brad Schenkel has authored 62 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Immunology, 16 papers in Economics and Econometrics and 14 papers in Dermatology. Recurrent topics in Brad Schenkel's work include Psoriasis: Treatment and Pathogenesis (31 papers), Health Systems, Economic Evaluations, Quality of Life (16 papers) and Dermatology and Skin Diseases (14 papers). Brad Schenkel is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (31 papers), Health Systems, Economic Evaluations, Quality of Life (16 papers) and Dermatology and Skin Diseases (14 papers). Brad Schenkel collaborates with scholars based in United States, Belgium and Canada. Brad Schenkel's co-authors include Michael Jones, Lloyd S. Ibels, Martin Zagari, Chenglong Han, Philippe Szapary, Tsen‐Fang Tsai, Mingliang Zhang, Chao‐Hsiun Tang, Sheng-Tzu Hung and Newman Yeilding and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Brad Schenkel

57 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Impact of epoetin alfa on clinical end points in patients with chronic renal failure: A meta-analysis

2004 564 citations Michael Jones, Brad Schenkel et al. profile →

Peers

Brad Schenkel

IMMUN

HEMAT

DERMA

NEPHR

Lars Erik Kristensen Denmark

Chenglong Han United States

Cathy Zhao Australia

Karen Douglas United Kingdom

Sella Aarrestad Provan Norway

Christian Sieder Germany

Peter T. Silberstein United States

C. Roubille France

Richard P. Polisson United States

Markus Bredemeier Brazil

Lars Erik Kristensen Denmark

Brad Schenkel

1.6k ×1.6

IMMUN

934 ×1.5

HEMAT

237 ×0.4

DERMA

169 ×0.6

NEPHR

166 ×0.8

Citations per year, relative to Brad Schenkel Brad Schenkel (= 1×) peers Lars Erik Kristensen

Countries citing papers authored by Brad Schenkel

Since Specialization

Citations

This map shows the geographic impact of Brad Schenkel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brad Schenkel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brad Schenkel more than expected).

Fields of papers citing papers by Brad Schenkel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brad Schenkel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brad Schenkel. The network helps show where Brad Schenkel may publish in the future.

Co-authorship network of co-authors of Brad Schenkel

This figure shows the co-authorship network connecting the top 25 collaborators of Brad Schenkel. A scholar is included among the top collaborators of Brad Schenkel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brad Schenkel. Brad Schenkel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Karpecki, Paul, et al.. (2023). Real-world treatment patterns of OTX-101 ophthalmic solution, cyclosporine ophthalmic emulsion, and lifitegrast ophthalmic solution in patients with dry eye disease: a retrospective analysis. BMC Ophthalmology. 23(1). 443–443. 8 indexed citations

Bhatia, Neal, et al.. (2023). 42295 Safety of tildrakizumab in a Phase 4 real-world study in patients with moderate-to-severe plaque psoriasis. Journal of the American Academy of Dermatology. 89(3). AB85–AB85.

Bhatia, Neal, et al.. (2023). CO220 Real-World Effectiveness and Safety in a Phase 4 Study of Tildrakizumab in Patients with Moderate-to-Severe Plaque Psoriasis. Value in Health. 26(6). S57–S57.

Bhatia, Neal, et al.. (2023). 42293 Real-world effectiveness of tildrakizumab in a Phase 4 study in patients with moderate-to- severe plaque psoriasis. Journal of the American Academy of Dermatology. 89(3). AB216–AB216.

Rozzo, Stephen J., et al.. (2023). 42290 Patients’ quality of life in a Phase 4 real-world study of tildrakizumab in moderate-to-severe plaque psoriasis. Journal of the American Academy of Dermatology. 89(3). AB204–AB204.

Karpecki, Paul, et al.. (2023). PCR136 A Retrospective Analysis of Real-World Treatment Patterns in Patients over Age 64 with Dry Eye Disease Receiving OTX-101 Ophthalmic Solution 0.09%, Cyclosporine Ophthalmic Emulsion 0.05%, or Lifitegrast Ophthalmic Solution 5%. Value in Health. 26(6). S337–S337. 2 indexed citations

Samlowski, Wolfram E., Nicholas J. Robert, Liwei Chen, et al.. (2022). Real‐World nivolumab dosing patterns and safety outcomes in patients receiving adjuvant therapy for melanoma. Cancer Medicine. 12(3). 2378–2388. 3 indexed citations

Wu, E, et al.. (2019). PCN115 ECONOMIC EVALUATIONS OF SUBCUTANEOUSLY ADMINISTERED ONCOLOGY THERAPIES: A HEALTH TECHNOLOGY ASSESSMENT (HTA) LANDSCAPE REVIEW. Value in Health. 22. S77–S77. 1 indexed citations

Feldman, Steven R., Susan D. Mathias, Brad Schenkel, et al.. (2014). Development Of A Patient-Reported Outcomes Measure For Psoriasis: The Psoriasis Symptoms, Signs, And Impact Questionnaire. Value in Health. 17(3). A289–A289. 1 indexed citations

10.

Odom, Dawn, Anita J. Brogan, Sandra E. Talbird, & Brad Schenkel. (2013). A network meta-analysis of randomized, controlled trials of ustekinumab and adalimumab for moderate-to-severe psoriasis. Value in Health. 16(3). A112–A112. 3 indexed citations

11.

Nakagawa, Hidemi, et al.. (2012). Impact of ustekinumab on health‐related quality of life in Japanese patients with moderate‐to‐severe plaque psoriasis: Results from a randomized, double‐blind, placebo‐controlled phase 2 / 3 trial. The Journal of Dermatology. 39(9). 761–769. 28 indexed citations

12.

Yeilding, Newman, Philippe Szapary, Carrie Brodmerkel, et al.. (2012). Development of the IL‐12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives – an update. Annals of the New York Academy of Sciences. 1263(1). 1–12. 22 indexed citations

13.

Pan, Feng, et al.. (2011). Cost Utility Analysis Based on a Head-to-Head Phase 3 Trial Comparing Ustekinumab and Etanercept in Patients with Moderate-to-Severe Plaque Psoriasis: A Canadian Perspective. Value in Health. 14(5). 652–656. 25 indexed citations

14.

Yeilding, Newman, Philippe Szapary, Carrie Brodmerkel, et al.. (2011). Development of the IL‐12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives. Annals of the New York Academy of Sciences. 1222(1). 30–39. 60 indexed citations

15.

Tsai, Tsen‐Fang, et al.. (2011). Epidemiology and comorbidities of psoriasis patients in a national database in Taiwan. Journal of Dermatological Science. 63(1). 40–46. 262 indexed citations

16.

Langley, Richard G., Steven R. Feldman, Chenglong Han, et al.. (2010). Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial. Journal of the American Academy of Dermatology. 63(3). 457–465. 181 indexed citations

17.

Prince, H. Miles, Brad Schenkel, & Linda Mileshkin. (2007). An analysis of clinical trials assessing the efficacy and safety of single-agent thalidomide in patients with relapsed or refractory multiple myeloma. Leukemia & lymphoma. 48(1). 46–55. 37 indexed citations

18.

Jones, Michael, et al.. (2005). Epoetin alfa's effect on left ventricular hypertrophy and subsequent mortality. International Journal of Cardiology. 100(2). 253–265. 13 indexed citations

19.

Jones, Michael, et al.. (2004). Epoetin alfa improves quality of life in patients with cancer. Cancer. 101(8). 1720–1732. 69 indexed citations

20.

Rossmanith, Winfried G., Brad Schenkel, & R. Benz. (1994). Role of androgens in the regulation of the human menstrual cycle. Gynecological Endocrinology. 8(3). 151–159. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact